Search results for "interactions."

showing 10 items of 1865 documents

Treatment outcome of invasive mould disease after sequential exposure to azoles and liposomal amphotericin B

2009

Objectives To analyse the potential antagonism between azoles, which inhibit ergosterol synthesis, and polyenes, which bind directly to ergosterol in cell membranes, in patients receiving sequential azole-polyene treatment. Methods In an earlier randomized, double blind study of liposomal amphotericin as initial therapy for invasive filamentous fungal infection (IFFI), a 3 mg/kg/day dose had a favourable overall response rate of 50% and 12 week survival rate of 72%. No improved outcome was seen with 10 mg/kg/day for the first 14 days. The study population was further analysed for the effect of prior azole exposure on treatment responses to liposomal amphotericin B. The protocol allowed prio…

AdultAzolesMaleMicrobiology (medical)medicine.medical_specialtyAntifungal AgentsAdolescentmedicine.drug_classAntibioticsPharmacologyAspergillosisGastroenterologyYoung AdultPharmacotherapyDouble-Blind MethodAmphotericin BInternal medicineAmphotericin BmedicineHumansDrug InteractionsPharmacology (medical)ChildSurvival rateMycosisAgedPharmacologyVoriconazolechemistry.chemical_classificationbusiness.industryInfantMiddle Agedmedicine.diseaseTreatment OutcomeInfectious DiseasesMycoseschemistryChild PreschoolAzoleFemalebusinessmedicine.drugJournal of Antimicrobial Chemotherapy
researchProduct

Inhibition of dextromethorphan metabolism by moclobemide.

1998

This pilot study was conducted to evaluate the potential of the new antidepressant moclobemide to inhibit the cytochrome enzyme P4502D6 (CYP2D6) using the cough suppressant dextromethorphan as a substrate in four extensive metabolizers (EM) of debrisoquine. The subjects received seven oral doses of 20 mg dextromethorphan at 4-h intervals over 2 days (1 and 2) and subsequently moclobemide (300 mg b.i.d.) for 9 days. On days 10 and 11, they received seven doses of 20 mg dextromethorphan in addition to moclobemide. During monotreatment and combined treatment, blood was collected on days 2 and 11, respectively, for determination of dextromethorphan and its demethylated metabolites using automat…

AdultCYP2D6animal structuresMonoamine Oxidase InhibitorsAdolescentMoclobemidePharmacologyDextromethorphanchemistry.chemical_compoundPharmacokineticsOral administrationDextrorphanMoclobemideMedicineHumansDrug InteractionsBiotransformationPharmacologybusiness.industryDextromethorphanDrug interactionAntidepressive AgentsDebrisoquinechemistryArea Under CurveBenzamidesbusinessmedicine.drugPsychopharmacology
researchProduct

Generalized Linear Model (GLM) framework for the association of host variables and viral strains with liver fibrosis in HCV/HIV coinfected patients

2012

Chronic hepatitis C virus (HCV) infection is the main cause of advanced and end-stage liver disease world-wide, and an important factor of morbidity and mortality in Human Immunodeficiency virus-1 (HIV-1) co-infected individuals. Whereas the genetic variability of HCV has been studied extensively in monoinfected patients, comprehensive analyses of both patient and virus characteristics are still scarce in HCV/HIV co-infection. In order to find correlates for liver damage, we sought to analyze demographic, epidemiological and clinical features of HCV/HIV co-infected patients along with the genetic makeup of HCV (viral subtypes and lineage studied by nucleotide sequencing and phylogenetic ana…

AdultLiver CirrhosisMaleMicrobiology (medical)medicine.medical_specialtyHepatitis C virusHIV InfectionsHepacivirusViral Nonstructural ProteinsBiologymedicine.disease_causeModels BiologicalMicrobiologyViruschemistry.chemical_compoundLiver diseaseFibrosisEpidemiologyGeneticsmedicineHumansGenetic variabilityMolecular BiologyNS5BPhylogenyEcology Evolution Behavior and SystematicsRetrospective StudiesPhylogenetic treeCoinfectionvirus diseasesHepatitis C ChronicMiddle Agedmedicine.diseaseVirologyInfectious DiseaseschemistryHost-Pathogen InteractionsImmunologyLinear ModelsFemaleInfection, Genetics and Evolution
researchProduct

The effects of prebiotics on microbial dysbiosis, butyrate production and immunity in HIV-infected subjects

2017

Altered interactions between the gut mucosa and bacteria during HIV infection seem to contribute to chronic immune dysfunction. A deeper understanding of how nutritional interventions could ameliorate gut dysbiosis is needed. Forty-four subjects, including 12 HIV+ viremic untreated (VU) patients, 23 antiretroviral therapy-treated (ART(+)) virally suppressed patients (15 immunological responders and 8 non-responders) and 9 HIV- controls (HIV-), were blindly randomized to receive either prebiotics (scGOS/lcFOS/glutamine) or placebo (34/10) over 6 weeks in this pilot study. We assessed fecal microbiota composition using deep 16S rRNA gene sequencing and several immunological and genetic marker…

AdultMale0301 basic medicine030106 microbiologyImmunologyHIV InfectionsInflammationButyrateBiologyGut floraMicrobiologyFeces03 medical and health sciencesIntestinal mucosaImmunityRNA Ribosomal 16SmedicineHumansImmunology and AllergyIntestinal MucosaBacteriaImmunityMiddle AgedPlacebo Effectmedicine.diseasebiology.organism_classificationGastrointestinal MicrobiomeGlutamineButyratesPrebiotics030104 developmental biologyMucosal immunologyDietary SupplementsHost-Pathogen InteractionsImmunologyHIV-1DysbiosisFemalemedicine.symptomDysbiosisMucosal Immunology
researchProduct

Effect of single-dose and short-term administration of quercetin on the pharmacokinetics of talinolol in humans – Implications for the evaluation of …

2013

Quercetin has been shown to inhibit intestinal P-glycoprotein-mediated drug efflux. A crossover clinical study was performed in 10 healthy volunteers to assess the effect of single-dose and repeated quercetin intake on the pharmacokinetics of talinolol, a substrate of intestinal P-glycoprotein. Unexpectedly, mean area under the plasma concentration-time curve (AUC0-48h) and maximal plasma concentration (cmax) were slightly decreased following concomitant and short-term quercetin administration (3186.0 versus 2468.3 and 2527.7 ng h/ml, p>0.05; 309.7 versus 212.0 and 280.6 ng/ml, p>0.05). Individual analysis revealed that talinolol AUC0-48h was lowered by 23.9% up to 60.6% in 5 subjects and c…

AdultMaleATP Binding Cassette Transporter Subfamily BFlavonoidCmaxAdministration OralPharmaceutical SciencePharmacologyDrug Administration SchedulePropanolaminesYoung Adultchemistry.chemical_compoundPharmacokineticsHumansDrug Interactionsheterocyclic compoundsIntestinal MucosaP-glycoproteinchemistry.chemical_classificationCross-Over StudiesDose-Response Relationship DrugbiologyBiological TransportTransporterMiddle AgedHealthy VolunteersIntestineschemistrybiology.proteinFemaleQuercetinEffluxQuercetinTalinololEuropean Journal of Pharmaceutical Sciences
researchProduct

Pharmacokinetic Interactions of Clozapine With Selective Serotonin Reuptake Inhibitors

1998

Pharmacokinetic interactions of clozapine and its metabolites N-desmethylclozapine and clozapine N-oxide with the selective serotonin reuptake inhibitors (SSRIs) fluvoxamine and paroxetine were investigated in a prospective study in schizophrenic patients under steady-state conditions. Thirty patients were treated with clozapine at a target dose of 2.5 to 3.0 mg/kg of body weight. After gradual dose escalation, serum concentrations of clozapine and two metabolites were determined twice at 7-day intervals after steady-state conditions had been reached. Then, fluvoxamine (50 mg/day) or paroxetine (20 mg/day) was added in 16 and 14 patients, respectively. Serum concentrations of clozapine and …

AdultMaleAdolescentFluvoxaminePharmacologyPharmacokineticsmedicineHumansDrug InteractionsPharmacology (medical)Prospective StudiesProspective cohort studyClozapineClozapinebusiness.industrySmokingMiddle AgedDrug interactionParoxetineParoxetinePsychiatry and Mental healthFluvoxamineSchizophreniaFemaleSerotoninbusinessReuptake inhibitorSelective Serotonin Reuptake InhibitorsAntipsychotic Agentsmedicine.drugJournal of Clinical Psychopharmacology
researchProduct

Addition of Low-Dose Fluvoxamine to Low-Dose Clozapine Monotherapy in Schizophrenia: Drug Monitoring and Tolerability Data from a Prospective Clinica…

1999

Combining fluvoxamine and clozapine may be a strategy to improve therapeutic effects on negative symptoms in schizophrenic patients. Fluvoxamine, however, markedly inhibits the metabolism of clozapine, and hazardous side effects may result. This study prospectively investigated the safety and tolerability of an add-on therapy with fluvoxamine to a clozapine monotherapy in schizophrenic patients. Sixteen schizophrenic patients received 50 mg fluvoxamine as a comedication after having reached steady-state conditions under clozapine monotherapy. Patients were monitored for subjective adverse events, laboratory parameters, EEG and ECG recordings, orthostatic hypotension and their psychopatholog…

AdultMaleAdolescentMatched-Pair AnalysisFluvoxamineDrug Administration ScheduleOrthostatic vital signsmedicineHumansDrug InteractionsPharmacology (medical)Prospective StudiesAdverse effectClozapineClozapineTherapeutic effectGeneral MedicineMiddle AgedDrug interactionPsychiatry and Mental healthTreatment OutcomeTolerabilityFluvoxamineAnesthesiaSchizophreniaAntidepressive Agents Second-GenerationDrug Therapy CombinationFemaleDrug MonitoringPsychologyReuptake inhibitorSelective Serotonin Reuptake InhibitorsAntipsychotic Agentsmedicine.drugPharmacopsychiatry
researchProduct

Executive and arousal vigilance decrement in the context of the attentional networks: The ANTI-Vea task

2018

Vigilance is generally understood as the ability to detect infrequent critical events through long time periods. In tasks like the Sustained Attention to Response Task (SART), participants tend to detect fewer events across time, a phenomenon known as vigilance decrement. However, vigilance might also involve sustaining a tonic arousal level. In the Psychomotor Vigilance Test (PVT), the vigilance decrement corresponds to an increment across time in both mean and variability of reaction time. New Method: The present study aimed to develop a single task Attentional Networks Test for Interactions and Vigilance executive and arousal components (ANTI-Vea) to simultaneously assess both components…

AdultMaleAdolescentmedia_common.quotation_subjectVIGILANCE DECREMENTNeuropsychological TestsPhasic alertnessbehavioral disciplines and activities050105 experimental psychologyArousalCIENCIAS SOCIALESExecutive FunctionYoung Adult03 medical and health sciences0302 clinical medicineSingle taskReaction TimeHumansAttention0501 psychology and cognitive sciencesAROUSAL VIGILANCEmedia_commonPsychomotor learningPSYCHOMOTOR VIGILANCE TEST (PVT)General Neuroscience05 social sciencesOtras PsicologíaResponse biasPsicologíaSUSTAINED ATTENTION TO RESPONSE TASK (SART)EXECUTIVE VIGILANCEFemaleArousalPsychologyPsychomotor Performance030217 neurology & neurosurgeryATTENTIONAL NETWORKS TEST-INTERACTIONS (ANT-I)Cognitive psychologyVigilance (psychology)Journal of Neuroscience Methods
researchProduct

Dose-dependent absorption and elimination of cefadroxil in man.

1991

The pharmacokinetic behaviour of cefadroxil was dose-dependent in healthy male volunteers following the oral administration of single doses of 5, 15, and 30 mg.kg-1. As the dose of cefadroxil increased from 5 to 15 and 30 mg.kg-1, the peak plasma concentrations, normalized to 5 mg.kg-1, decreased significantly from 15.1 to 10.7 and 7.6 mg.l-1, while the corresponding normalized areas under the plasma concentration-time curves from 0 to 2 h decreased significantly from 1258 to 946 and 801 min.mg.l-1. When the same subjects were given 5 mg.kg-1 of cefadroxil together with 45 mg.kg-1 of cephalexin, the absorption of cefadroxil was slowed to a similar or greater extent than with the high dose o…

AdultMaleAdolescentmedicine.drug_classMetabolic Clearance RateAntibioticsAbsorption (skin)PharmacologyKidneyAbsorptionPharmacokineticsOral administrationReference ValuesmedicineHumansPharmacology (medical)Drug InteractionsPharmacologyCephalexinDose-Response Relationship DrugChemistryCefadroxilKidney metabolismGeneral MedicineDrug interactionDose–response relationshipCefadroxilmedicine.drugEuropean journal of clinical pharmacology
researchProduct

The Influence of Chitosan on the Oral Bioavailability of Acyclovir-a Comparative Bioavailability Study in Humans

2015

Purpose The effects of chitosan hydrochloride on the oral absorption of acyclovir in humans were studied to confirm the absorption enhancing effects reported for in vitro and rat studies, respectively. Methods A controlled, open-label, randomized, 3-phase study was conducted in 12 healthy human volunteers. Zovirax 200 mg dispersible tablets co-administered with doses of 400 and 1000 mg chitosan HCl were compared with Zovirax only. Results The expected increased absorption of acyclovir was not observed. On the contrary, mean area under the plasma concentration-time curve (AUC0-12 h) and maximal plasma concentration (Cmax) decreased following concomitant chitosan intake (1402 versus 1017 and …

AdultMaleBioavailability StudyAcyclovirAdministration OralBiological AvailabilityPharmaceutical Science02 engineering and technologyAbsorption (skin)PharmacologyAntiviral Agents030226 pharmacology & pharmacyHealthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18]Chitosan03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePharmacokineticsbiopharmaceutics classification systemHumansMedicinePharmacology (medical)Chromatography High Pressure LiquidPharmacologyChitosanDrug Carriersbusiness.industryOrganic Chemistry021001 nanoscience & nanotechnologyBiopharmaceutics Classification SystembiowaiverHealthy Volunteers3. Good healthBioavailabilitychemistryexcipient interactionsData Interpretation StatisticalMolecular MedicineFemaleChitosan hydrochloridebioavailability0210 nano-technologybusinesspharmacokineticsResearch PaperBiotechnologyBiological availabilityPharmaceutical Research
researchProduct